Medtronic expand uro u.s. clinical trial meets safety and effectiveness primary endpoints for hugo™ robotic-assisted surgery system

Largest multi-center prospective investigational device exemption (ide) study for multi-port robotic-assisted urologic surgery in the u.s. presented as a late-breaker at the american urologic association annual meeting  company confirms hugo ras system submission to the u.s. food and drug administration galway, ireland and las vegas , april 26, 2025 /prnewswire/ -- medtronic (nyse: mdt), a global leader in healthcare technology, today announced that the expand uro investigational device exemption (ide) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. the prospective, multi-center, single-arm ide study included 137 patients who underwent urologic procedures using the hugo™ robotic-assisted surgery (ras) system.
MDT Ratings Summary
MDT Quant Ranking